Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


18 Items
Title  Creator  Group name  Publishing year 
[68Ga]Ga-FAPI-46 synthesis on a GAIA® module system: Thorough study of the automated radiolabeling reaction conditions Rubira et al. EquipeJPP 2024-04
Towards Optimal Automated 68Ga-Radiolabeling Conditions of the DOTA-Bisphosphonate BPAMD Without Pre-Purification of the Generator Eluate Souche et al. EquipeJPP 2024-11-20
New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer Hébert et al. EquipeJPP 2024-07
Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine Hebert et al. EquipeJPP 2024-06-03
"One Method to Label Them All": A Single Fully Automated Protocol for GMP-Compliant 68Ga Radiolabeling of PSMA-11, Transposable to PSMA-I&T and PSMA-617 Fouillet et al. EquipeJPP 2024
Prevention of post-hepatectomy liver failure after major resection of colorectal liver metastases: is hepato-biliary scintigraphy the optimal tool? Cusumano et al. EquipeJPP 3/2023
Bisphosphonates as Radiopharmaceuticals: Spotlight on the Development and Clinical Use of DOTAZOL in Diagnostics and Palliative Radionuclide Therapy Souche et al. EquipeJPP 2023-12-29
225Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic Rubira et al. EquipeJPP 2023-03-24
Unusual Focal Lung Uptake without CT Abnormality on a Bone Scan: What Might It Mean? Eberlé et al. EquipeJPP 2022-04-08
Tailored Media-Fill Test Protocols Inspired by 68Ga Kit-Based Radiopharmaceuticals Donzé et al. EquipeJPP 2022
Lumbosacral Plexus Neurolymphomatosis: A Typical 18FDG PET/CT Pattern to Recognize Bordeau et al. EquipeJPP 4/2022
Development and Implementation of a Professional Practices Evaluation during Radiopharmaceuticals Administration Donzé et al. EquipeJPP 2022-11-10
AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications Fersing et al. EquipeJPP 2022-02-16
177 Lu-Dotatate administration using an infusion pump or a peristaltic pump: comparison of two methods Donzé et al. EquipeJPP 2022-09-13
Whole body planar and 3D quantitative imaging after 177Lu-DOTATATE on CZT SPECT/CT device with MEHRS collimator. First report Deshayes et al. EquipeJPP 2021
Implementation and validation of an in-house combined fluorescein/media-fill test to qualify radiopharmacy operators Fersing et al. EquipeJPP 2021-01-07
Synthesis and in vitro antitumour activity of carboplatin analogues containing functional handles compatible for conjugation to drug delivery systems Re?nik et al. EquipeCG 2020-11-15
Antiviral (Hepatitis C Virus) Drug-Drug Interaction Leading to Dramatic Underestimation of Liver Function With 99mTc-Mebrofenin Hepatobiliary Scintigraphy Deshayes et al. EquipePM Feb 2020
18 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés